HK-listed Alphamab hits 2-month high on breast cancer drug licensing deal
04/08/2026 06:58
BUZZ-HK-listed Alphamab hits 2-month high on breast cancer drug licensing deal ** Shares of Alphamab Oncology 9966.HK jump as much as 12.8% to HK$8.35, their highest point since June 2
** Stock last up 5.7%, on track for the biggest one-day pct gain since July 20; snapping two straight falling sessions
** New York City-based Pathos AI will pay $125 million upfront to a subsidiary of Alphamab Oncology 9966.HK for rights to an experimental drug for a type of breast cancer, the Chinese oncology specialist said Tuesday, as it competes with bigger rivals
** YTD, stock down 20.2%, while benchmark Hang Seng Index .HSI up 0.6%
(Reporting by Donny Kwok)
Recent news on Alphamab Oncology
See all newsBrief: Alphamab Oncology Says Fei Wang Resigns As Chief Financial Officer
Brief: Alphamab Oncology Says First Patient Dosed In Phase III Clinical Study Of JSKN033 Monotherapy For Treatment Of Cervical Cancer
Brief: Alphamab Oncology Says Board Resolves To Repurchase Shares Up To HK$80 Million In Value
Brief: Alphamab Oncology Says NMPA Accepts NDA For Anbenitamab With HB1801 For Her2+ Advanced Breast Cancer
Brief: Alphamab Oncology Says NMPA Accepts NDA For Anbenitamab (KN026)